1-(4-Amino-3,5-dichloro-phenyl)-2-(1-ethyl-1-methyl-propylamino)-ethanol | 38339-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Amino-3,5-dichloro-phenyl)-2-(1-ethyl-1-methyl-propylamino)-ethanol
• 英文别名: 4-Amino-3,5-dichloro-alpha-(((1-ethyl-1-methylpropyl)amino)methyl)benzenemethanol；1-(4-amino-3,5-dichlorophenyl)-2-(3-methylpentan-3-ylamino)ethanol
• CAS: 38339-24-1
• 化学式: C₁₄H₂₂Cl₂N₂O
• 分子量: 305.247
• InChiKey: OYESZEHLQBILOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Bronchodilating compositions and methods
  申请人：Dey L.P.

  公开号：US20020151597A1

  公开（公告）日：2002-10-17

  Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

  提供支气管扩张剂组合物和方法。这些组合物旨在作为雾化气溶胶进行管理。在某些实施例中，这些组合物含有福莫特罗或其衍生物。还提供使用此处提供的组合物治疗、预防或改善支气管收缩性疾病的一个或多个症状的方法。
• Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
  申请人：PIPKIN D. JAMES

  公开号：US20070202054A1

  公开（公告）日：2007-08-30

  An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

  提供了一种含有SAE-CD和类固醇的可吸入制剂。该制剂适用于通过任何已知的雾化器对受试者进行雾化给药。该制剂可以包含在套件中。该制剂以水溶液形式给予，但可以存储为干粉、即用溶液或浓缩组成。该制剂用于改进的雾化系统中，通过吸入给药类固醇。制剂中的SAE-CD显著增强了布地奈德的化学稳定性。提供了一种通过吸入给药该制剂的方法。该制剂也可以通过传统的鼻腔给药装置进行给药。
• Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions
  申请人：Pipkin James D.

  公开号：US20090312724A1

  公开（公告）日：2009-12-17

  The present invention is directed to methods of treating nasal and/or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to methods, systems, devices, and compositions for delivering aqueous solution formulations comprising a corticosteroid and an antihistamine to nasal and ophthalmic tissues.

  本发明涉及通过给鼻腔和眼科组织提供含有皮质类固醇的水溶液制剂，治疗对皮质类固醇疗法有治疗反应的鼻部和/或眼科疾病、症状或障碍的方法。本发明还涉及用于给鼻腔和眼科组织提供含有皮质类固醇和抗组胺剂的水溶液制剂的方法、系统、装置和组合物。
• DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
  申请人：CyDex Pharmaceuticals, Inc.

  公开号：EP2708225A1

  公开（公告）日：2014-03-19

  An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physiochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delievered by DPI when SAE-CD is used as a carrier.

  提供了一种含有 SAE-CD 和活性剂的可吸入干粉制剂。该制剂适用于 DPI 给药。SAE-CD 可作为载体而非吸收促进剂。SAE-CD 的平均粒径大到足以排除（大部分）肺部沉积。从干粉吸入器中释放出来后，含 SAE-CD 的微粒会在颊腔或喉咙中与含活性剂的微粒分离，然后含活性剂的微粒会继续深入呼吸道。SAE-CD 的理化和形态特性很容易改变，可以优化活性剂和载体之间的相互作用。当 SAE-CD 用作载体时，具有正、中或负静电荷的药物可通过 DPI 释放。
• INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID
  申请人：CyDex Pharmaceuticals, Inc.

  公开号：EP3238708A1

  公开（公告）日：2017-11-01

  An inhalable formulation comprising SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

  提供了一种由 SAE-CD 和皮质类固醇组成的可吸入制剂。该制剂可通过任何已知的雾化器雾化给药。该制剂可包含在试剂盒中。该制剂以水溶液形式给药，但也可以干粉、即用溶液或浓缩组合物的形式储存。该制剂可用于改进的雾化系统，通过吸入给药皮质类固醇。制剂中的 SAE-CD 可显著提高布地奈德的化学稳定性。该制剂还提供了一种吸入给药方法。该制剂也可通过传统的鼻腔给药装置给药。